University of Wisconsin Meditation & Exercise Cold Study (MEPARI-2)
The primary goal of this project is to determine whether behavioral training in mindfulness meditation or moderate intensity sustained exercise will lead to reductions in acute respiratory infection (ARI) illness, such as common cold and influenza like illness. Specifically, this project aims to:
- Determine whether an 8-week training program in mindfulness meditation, as compared to the control group, will lead to significant reductions in incidence, duration, and severity of ARI illness.
- Determine whether an 8-week training program in moderate intensity sustained exercise, as compared to the control group, will lead to reductions in incidence, duration, and severity of ARI illness.
- Assess whether any observed reductions in ARI illness are accompanied by fewer ARI-related health care visits and less time lost to productive work (reduced absenteeism).
- Compare the potential benefits of mindfulness meditation to those from moderate intensity sustained exercise.
- Discern potential mediating factors and causal pathways that might help explain how these interventions lead to improved ARI illness-related outcomes.
The investigators' preliminary findings suggest substantial benefit of these interventions in terms of reduced incidence, duration and severity of ARI illness, with corresponding reductions in days of work lost to illness. If the proposed research confirms these findings, there will be major implications for public and private health-related policy and practice, as well as for scientific knowledge regarding health maintenance and disease prevention.
Acute Respiratory Infection
Other: Mindfulness Meditation
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Meditation or Exercise for Preventing Acute Respiratory Infection (MEPARI-2)|
- Severity-weighted total days of ARI illness [ Time Frame: 8 months ] [ Designated as safety issue: No ]The primary outcome will be severity-weighted total days of ARI illness (global severity), calculated as trapezoidal approximation to area under the time severity curve during ARI illness, with severity assessed once daily using self-reports on the validated Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Incidence (number of ARI episodes in each group) and duration (total number of days of ARI illness) are components of the primary outcome, and will be analyzed separately.
- Absenteeism [ Time Frame: 8 months ] [ Designated as safety issue: No ]Employment, including type of work, hours per week worked, and compensation, assessed as hourly wage, will be assessed at enrollment. Each week throughout the study participants will complete questions to assess number of hours of work missed. Study personnel blinded to allocation group status will assess and classify reasons for missed work as either ARI-related or not ARI-related.
- Health Care Utilization [ Time Frame: 8 months ] [ Designated as safety issue: No ]Total number of health care visits, ARI-related health care visits, and ARI-related prescriptions, including antibiotics and anti-influenza anti-virals will be documented. Each weekly communication will include the question, "Have you seen a doctor or visited a clinic, hospital or urgent care center?" Persons answering "Yes" will be asked the reason for the visit. Those answers will then be classified by blinded study personnel as either "Related," or "Unrelated" to ARI illness, including upper respiratory infection, influenza, pharyngitis, acute sinusitis, bronchitis, and pneumonia.
- SF-12 [ Time Frame: 8 months ] [ Designated as safety issue: No ]Also known as the Medical Outcomes Study Short Form, this 12-item questionnaire is commonly used to measure overall health, including physical (SF12-P) and mental health (SF12-M) subscales. It has been extensively assessed for reliability, responsiveness and criterion validity. In this study, it will be used to assess potential changes in general physical and mental health due to interventions, and as a covariate to control for baseline between-person differences in multivariate efficacy analyses.
- Perceived Stress Scale (PSS-10) [ Time Frame: 8 months ] [ Designated as safety issue: No ]The PSS-10 has been validated in multiple studies. PSS scores predict rates of viral infection among volunteers inoculated with rhinovirus, and correlate with physiologic and self-report indicators of ARI illness, including nasal IL-6 level. Because stress reduction is one of the hypothesized mechanisms of action, this study population will include working-age participants, who are presumed to be more stressed.
- Mindfulness-based Self Efficacy Scale (MSES) [ Time Frame: 8 months ] [ Designated as safety issue: No ]Research aimed at defining and assessing the concept of "mindfulness" is well underway, with several questionnaire instruments available. The MSES is one of the more recent questionnaires, developed by Cayoun and Freestun to assess effects of MBSR training on perceived self-efficacy. The MSES assesses 7 domains related to mindfulness self-efficacy, including behavior, cognition, interoception, affect, interpersonal, avoidance and mindfulness. The MSES will provide a nice counterpart to the ESES to help distinguish effects of interventions on ARI outcomes.
- Exercise Self-Efficacy Scale (ESES) [ Time Frame: 8 months ] [ Designated as safety issue: No ]Self-efficacy has been defined as "the belief in one's capabilities to organize and execute the courses of action required to manage prospective situations." The ESES scale was developed based on work by Bandura and colleagues,and has been validated by Shin, Kroll,and Everett. For this study, the ESES will be used to verify results of the exercise intervention, and to help explain potential mediational effects of exercise.
- Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: 8 months ] [ Designated as safety issue: No ]Sleep quality has been linked to several important quality of life and health outcomes. The PSQI is widely used and has been assessed for reliability and validity.In this study, improved sleep is a potential mediator of intervention effects, and a potentially important outcome on its own.
- Body Mass Index (BMI) [ Time Frame: 8 months ] [ Designated as safety issue: No ]Body habitus is associated with many disease processes, and may be related to immune function and susceptibility to respiratory infection. Height will be assessed at baseline only. Weight will be measured at baseline, 1 and 4 months post-intervention, and at exit. Baseline BMI will be calculated and used as a covariate in statistical models. BMI will also be considered a secondary outcome of potential importance.
- Blood Pressure [ Time Frame: 8 months ] [ Designated as safety issue: No ]Standard brachial blood pressure will be assessed by trained nurses using calibrated sphygmomanometers.
- Pro-Inflammatory Cytokines [ Time Frame: 8 months ] [ Designated as safety issue: No ]Laboratory-assessed objective measures will primarily serve to corroborate self-reports of disease severity. High sensitivity C-reactive protein (HS-CRP) and procalcitonin (PCT) are well-established indicators of disease severity during respiratory infection, and can be measured in serum and in nasal wash.Concentrations of interleukin-6 (IL-6)and interleukin-8 (IL-8)in nasal wash have been shown to correlate with illness severity. More recently, interferon-gamma-induced protein 10 (IP-10) has been shown to be measurably increased in both serum and nasal wash during times of acute viral ARI.
|Study Start Date:||June 2012|
|Estimated Study Completion Date:||June 2017|
|Estimated Primary Completion Date:||June 2016 (Final data collection date for primary outcome measure)|
Experimental: Mindfulness Meditation
Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and approximately 45 minutes per day at-home daily practice.
Other: Mindfulness Meditation
Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation "retreat" on a weekend day at the end of week 6 will allow participants to practice their skills.
Other Name: MBSR
The exercise intervention structure is consistent with many standardized exercise programs. The exercise program will match the meditation program in duration (8 weeks), attention (weekly 2½ hour group sessions), and intensity (daily 45 minute at-home practice).
Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
Other Name: physical activity
No Intervention: Wait-list control
Apart from not attending any of the specific meditation or exercise training sessions, those in the control group will be treated in essentially the same manner as "experimental" participants.
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01654289
|Contact: Shari Barlowemail@example.com|
|Contact: Michele Gassmanfirstname.lastname@example.org|
|United States, Wisconsin|
|University of Wisconsin Department of Family Medicine||Recruiting|
|Madison, Wisconsin, United States, 53715|
|Contact: Shari Barlow 608-333-2653 email@example.com|
|Contact: Michele Gassman 608-807-7227 firstname.lastname@example.org|
|Principal Investigator: Bruce Barrett, MD PhD|
|Sub-Investigator: Mary Hayney, PharmD|
|Sub-Investigator: Christopher Coe, PhD|
|Sub-Investigator: Daniel Muller, MD PhD|
|Sub-Investigator: David Rakel, MD|
|Sub-Investigator: Roger Brown, PhD|
|Sub-Investigator: Aleksandra Zgierska, MD PhD|
|Sub-Investigator: Zhengjun Zhang, PhD|
|Principal Investigator:||Bruce Barrett, MD PhD||University of Wisconsin Department of Family Medicine|